Preclinical animal study demonstrates oral delivery of GPX4 by engineered probiotics protects against sepsis in mice, suggesting a novel microbiome-targeted therapy.
Sepsis remains a leading cause of mortality worldwide, driven by dysregulated inflammation and organ failure, with limited targeted therapies. Pyroptosis, mediated by gasdermin D (GSDMD), amplifies sepsis pathology through lipid peroxidation-dependent mechanisms, yet direct interventions are scarce. Leveraging the probiotic Escherichia coli Nissle 1917 (EcN) for gut-targeted delivery, we engineered EcN to secrete glutathione peroxidase 4 (GPX4), a pivotal antioxidant enzyme that curbs lipid peroxidation and pyroptosis. In an LPS-induced murine sepsis model, prophylactic oral EcN-GPX4 enhanced survival, mitigated multi-organ damage, and suppressed GSDMD cleavage across tissues. Dual mechanisms included: alleviation of oxidative stress and lipid peroxidation to block pyroptosis; and gut microbiota remodeling, enriching Ligilactobacillus murinus, which correlated with reduced LPS translocation and dampened arachidonic acid–linked pro-inflammatory metabolism. Via the gut–liver axis, EcN-GPX4 further attenuated hepatic TLR4/NF-κB signaling. This probiotic-based enzyme delivery offers a precise, microbiome-modulating strategy to interrupt pyroptotic amplification, with strong translational promise for sepsis management.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: